UNCY:NASDAQ, Unicycive Therapeutics, Inc.

UNCY stock overview

Unicycive Therapeutics, Inc. (UNCY:NASDAQ) closed at $3.89 on October 23, 2026, down 1.27% on the day. The stock trades 55.5% below its 52-week high of $8.74 and 16.1% above its 52-week low of $3.35. Over the past year, it lost 24.2%. Unicycive Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price
$3.89
Day change
-1.27%
Volume
1,212,401
Average volume
869,384
Market cap
106M+
52-week range
$3.35 – $8.74
50-day average
$4.75
200-day average
$6.17

Price action over the past year

In 252 trading sessions since October 23, 2025, UNCY closed higher on 124 days (49%). Its best day was June 22, 2026 (+14.89%) and its worst was June 30, 2026 (-39.09%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

UNCY news

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Similar stocks

Find more stocks like UNCY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.